27649982|t|Ocular hypotensive effect of the novel EP3 / FP agonist ONO-9054 versus Xalatan: results of a 28- day, double-masked, randomised study
27649982|a|ONO-9054 is being developed for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) and open-angle glaucoma (OAG). This study compared the novel dual EP3 / FP agonist ONO-9054 with the FP agonist Xalatan. Adults (n=123) with bilateral mild/moderate OAG or OHT, with unmedicated IOP of ≥24 mm Hg at 8:00 hours, ≥21 mm Hg at 10:00 hours and ≤36 mm Hg, were randomised 1:1 to receive ONO-9054 (0.003%, 30 μg/mL) or Xalatan (0.005%, 50 μg/mL) once daily for 28 days. Day 29 mean diurnal IOP was -7.2 mm Hg for ONO-9054 vs -6.6 mm Hg for Xalatan. At 08:00 hours, the IOPs were comparable, and at all later time points the decrease in IOP was greater for ONO-9054. On day 29, the odds of a mean IOP reduction of ≤-25%, ≤-30% and ≤-35% for ONO-9054 were 2.39, 2.37 and 4.85 times more, respectively, than the odds for Xalatan (p<0.05, post hoc analyses). The percentage of subjects achieving target IOPs on day 29 (≤17, ≤16 and ≤15 mm Hg) was greater for ONO-9054 than for Xalatan; the odds of achieving an IOP ≤15 mm Hg for ONO-9054 were 2.4 times more than the odds for Xalatan (p<0.01, post hoc analysis). Subjects randomised to receive ONO-9054 were more likely to achieve a greater per cent reduction in IOP and were more likely to achieve target IOPs than those receiving Xalatan. The effects of ONO-9054 in reducing IOP appear to persist longer than those of Xalatan. NCT02083289, Results.
27649982	0	18	Ocular hypotensive	T038	UMLS:C0028841
27649982	39	42	EP3	T103	UMLS:C1449580
27649982	45	47	FP	T103	UMLS:C0662784
27649982	48	55	agonist	T103	UMLS:C2987634
27649982	56	64	ONO-9054	T103	UMLS:C4277062
27649982	72	79	Xalatan	T103	UMLS:C0593887
27649982	103	116	double-masked	T062	UMLS:C0013072
27649982	129	134	study	T062	UMLS:C2603343
27649982	135	143	ONO-9054	T103	UMLS:C4277062
27649982	184	204	intraocular pressure	T038	UMLS:C0021888
27649982	206	209	IOP	T038	UMLS:C0021888
27649982	228	247	ocular hypertension	T038	UMLS:C0028841
27649982	249	252	OHT	T038	UMLS:C0028841
27649982	258	277	open-angle glaucoma	T038	UMLS:C0017612
27649982	279	282	OAG	T038	UMLS:C0017612
27649982	290	295	study	T062	UMLS:C2603343
27649982	320	323	EP3	T103	UMLS:C1449580
27649982	326	328	FP	T103	UMLS:C0662784
27649982	329	336	agonist	T103	UMLS:C2987634
27649982	337	345	ONO-9054	T103	UMLS:C4277062
27649982	355	357	FP	T103	UMLS:C0662784
27649982	358	365	agonist	T103	UMLS:C2987634
27649982	366	373	Xalatan	T103	UMLS:C0593887
27649982	419	422	OAG	T038	UMLS:C0017612
27649982	426	429	OHT	T038	UMLS:C0028841
27649982	448	451	IOP	T038	UMLS:C0021888
27649982	551	559	ONO-9054	T103	UMLS:C4277062
27649982	582	589	Xalatan	T103	UMLS:C0593887
27649982	653	656	IOP	T038	UMLS:C0021888
27649982	676	684	ONO-9054	T103	UMLS:C4277062
27649982	703	710	Xalatan	T103	UMLS:C0593887
27649982	732	736	IOPs	T038	UMLS:C0021888
27649982	799	802	IOP	T038	UMLS:C0021888
27649982	819	827	ONO-9054	T103	UMLS:C4277062
27649982	859	862	IOP	T038	UMLS:C0021888
27649982	903	911	ONO-9054	T103	UMLS:C4277062
27649982	981	988	Xalatan	T103	UMLS:C0593887
27649982	998	1015	post hoc analyses	T062	UMLS:C0936012
27649982	1062	1066	IOPs	T038	UMLS:C0021888
27649982	1118	1126	ONO-9054	T103	UMLS:C4277062
27649982	1136	1143	Xalatan	T103	UMLS:C0593887
27649982	1170	1173	IOP	T038	UMLS:C0021888
27649982	1188	1196	ONO-9054	T103	UMLS:C4277062
27649982	1235	1242	Xalatan	T103	UMLS:C0593887
27649982	1252	1269	post hoc analysis	T062	UMLS:C0936012
27649982	1303	1311	ONO-9054	T103	UMLS:C4277062
27649982	1372	1375	IOP	T038	UMLS:C0021888
27649982	1415	1419	IOPs	T038	UMLS:C0021888
27649982	1441	1448	Xalatan	T103	UMLS:C0593887
27649982	1465	1473	ONO-9054	T103	UMLS:C4277062
27649982	1486	1489	IOP	T038	UMLS:C0021888
27649982	1529	1536	Xalatan	T103	UMLS:C0593887